Compare Merck & Co., Inc. (MRK) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs United Airlines Holdings Inc — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while United Airlines Holdings Inc trades at $118.05 (market cap $38.15B). The key difference: Merck & Co., Inc. is far larger — about 8.1× United Airlines Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| MRK | UAL | |
|---|---|---|
Market Cap | $307.25B | $38.15B |
Sector | Health | Industrials |
52-Week High | $129.52 | $136.11 |
52-Week Low | $77.60 | $84.57 |
Enterprise Value | $350.66B | $55.18B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
United Airlines (UAL) trades at $117.68, up 1.97% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.99 exceeding expectations. Revenue growth is robust, reaching $59.07B in 2025, and profitability metrics like a 5.56% net income margin and 23.25% ROE reflect operational strength. Recent news highlights labor agreements and resilient travel demand despite fuel cost pressures.
The outlook for UAL is positive, driven by strong travel demand and premium revenue growth, with a consensus price target of $163.75 implying significant upside. Risks include volatile fuel prices and operational disruptions, but the company's guidance for 2026 EPS of $9–$11 and improving cash flow trends support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
